WO2022220608A1 - Procédé de préparation d'un intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate - Google Patents
Procédé de préparation d'un intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate Download PDFInfo
- Publication number
- WO2022220608A1 WO2022220608A1 PCT/KR2022/005396 KR2022005396W WO2022220608A1 WO 2022220608 A1 WO2022220608 A1 WO 2022220608A1 KR 2022005396 W KR2022005396 W KR 2022005396W WO 2022220608 A1 WO2022220608 A1 WO 2022220608A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- solvent
- compound
- chloro
- reaction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 title abstract description 33
- 238000003786 synthesis reaction Methods 0.000 title abstract description 33
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 51
- 239000002904 solvent Substances 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000002425 crystallisation Methods 0.000 claims description 31
- 230000008025 crystallization Effects 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 239000012046 mixed solvent Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 239000003638 chemical reducing agent Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 238000006722 reduction reaction Methods 0.000 claims description 7
- 125000003158 alcohol group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000004210 ether based solvent Substances 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 150000004292 cyclic ethers Chemical class 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 150000001983 dialkylethers Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- XTRBBCJVBLRZPE-UHFFFAOYSA-N methyl 3-chloro-1-propan-2-ylindazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C(C)C)N=C(Cl)C2=C1 XTRBBCJVBLRZPE-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 14
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000007795 chemical reaction product Substances 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- XXWLKFLYCRSTFP-UHFFFAOYSA-N (3-chloro-1-propan-2-ylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C(C)C)N=C(Cl)C2=C1 XXWLKFLYCRSTFP-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 238000004190 ion pair chromatography Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 9
- -1 3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy Chemical group 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- FNSQPQKPPGALFA-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(O)=CC=C21 FNSQPQKPPGALFA-UHFFFAOYSA-N 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 239000000018 receptor agonist Substances 0.000 description 7
- QOFFFCUMPDREKF-UHFFFAOYSA-N 1-chloro-6-hydroxy-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(O)=CC=C21 QOFFFCUMPDREKF-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WNJWMBXSURBCBT-UHFFFAOYSA-N 1-chloro-6-[(3-chloro-1-propan-2-ylindazol-5-yl)methoxy]-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(OCC=3C=C4C(Cl)=NN(C4=CC=3)C(C)C)=CC=C21 WNJWMBXSURBCBT-UHFFFAOYSA-N 0.000 description 4
- GNZJLIGRTVGHMF-UHFFFAOYSA-N CC(C)N(C1=CC=C(CBr)C=C11)N=C1Cl Chemical compound CC(C)N(C1=CC=C(CBr)C=C11)N=C1Cl GNZJLIGRTVGHMF-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 4
- LPLOEZPPYOSNEW-UHFFFAOYSA-N methyl 1h-indazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NN=CC2=C1 LPLOEZPPYOSNEW-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BDKNTMQPRHCITN-UHFFFAOYSA-N 1-chloro-6-methoxy-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(OC)=CC=C21 BDKNTMQPRHCITN-UHFFFAOYSA-N 0.000 description 3
- MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 3
- FIQRFGMXMPFPRK-UHFFFAOYSA-N CC(C)N(C1=CC(COC(C=C2CC3)=CC=C2C(Cl)=C3C=O)=CC=C11)N=C1Cl Chemical compound CC(C)N(C1=CC(COC(C=C2CC3)=CC=C2C(Cl)=C3C=O)=CC=C11)N=C1Cl FIQRFGMXMPFPRK-UHFFFAOYSA-N 0.000 description 3
- FYBHCMAHQKJAFA-UHFFFAOYSA-N CC(C)N(C1=CC=C(COC(C=C2CCC3)=CC=C2C3=O)C=C11)N=C1Cl Chemical compound CC(C)N(C1=CC=C(COC(C=C2CCC3)=CC=C2C3=O)C=C11)N=C1Cl FYBHCMAHQKJAFA-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- GGULXYLLYYPWQZ-UHFFFAOYSA-N methyl 3-chloro-2h-indazole-5-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=NNC(Cl)=C21 GGULXYLLYYPWQZ-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 230000008209 cardiovascular development Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- GUVLZYAZFWASMH-UHFFFAOYSA-N methyl 1-propan-2-ylindazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C(C)C)N=CC2=C1 GUVLZYAZFWASMH-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 108010035597 sphingosine kinase Proteins 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- ZZMYWYZPNZRYPX-SANMLTNESA-N (2r)-2-amino-2-[5-[4-[2-(4-phenylphenyl)ethoxy]-3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]propan-1-ol Chemical compound N1C([C@@](N)(CO)C)=NC=C1C(C=C1C(F)(F)F)=CC=C1OCCC1=CC=C(C=2C=CC=CC=2)C=C1 ZZMYWYZPNZRYPX-SANMLTNESA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- NVJUHMXYKCUMQA-UHFFFAOYSA-N 1-ethoxypropane Chemical compound CCCOCC NVJUHMXYKCUMQA-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- ZLJNDKIJSSGTIQ-UHFFFAOYSA-N 1-propan-2-ylindazole Chemical compound C1=CC=C2N(C(C)C)N=CC2=C1 ZLJNDKIJSSGTIQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ZNJRONVKWRHYBF-UHFFFAOYSA-N 2-[2-[2-(1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-yl)ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound O1C(C)=CC(=C(C#N)C#N)C=C1C=CC1=CC(CCCN2CCC3)=C2C3=C1 ZNJRONVKWRHYBF-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- CTDGQGZDLANRLD-UHFFFAOYSA-N 3-chloro-1-propan-2-ylindazole Chemical compound C1=CC=C2N(C(C)C)N=C(Cl)C2=C1 CTDGQGZDLANRLD-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101000703517 Dictyostelium discoideum Sphingosine-1-phosphate lyase Proteins 0.000 description 1
- AQZGPSLYZOOYQP-UHFFFAOYSA-N Diisoamyl ether Chemical compound CC(C)CCOCCC(C)C AQZGPSLYZOOYQP-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 108010066791 sphingosine-1-phosphate phosphatase Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Definitions
- the present invention relates to a process for the preparation of key intermediates for the synthesis of sphingosine-1-phosphate receptor agonists.
- Sphingosine-1-phosphate is produced through the intracellular ceramide pathway, and ceramide, the starting material of this synthetic pathway, has two production pathways, namely, the de novo biosynthetic pathway and It is produced in cells through the degradation of sphingomyelin, a component of the cell membrane.
- S1P levels in each tissue are regulated by two biosynthetic sphingosine kinases (SphKs) and two biodegradable S1P phosphatases (S1P lyase and lysophospholipid phosphatases).
- S1P lyase and lysophospholipid phosphatases The produced substance S1P mediates various cellular responses such as cell proliferation, cytoskeletal organization and migration, adhesion- and tight junction assembly, and morphogenesis. it is known They are present in plasma at high concentrations (100-1000 nM) in a form bound to albumin and other plasma proteins, while in tissues at low concentrations.
- S1P binds to the S1P receptor, a G-protein coupled receptor, and exhibits various biological functions.
- the sub-types of S1P receptors known to date are S1P1 to S1P5. ) receptor) 1, 5, 3, 6 and 8. These S1P receptors are responsible for leukocyte recirculation, neural cell proliferation, morphological changes, migration, endothelial function, vasoregulation and cardiovascular development ( It is known to be involved in various biological functions such as cardiovascular development.
- S1P signaling through these receptors plays an important role in a series of responses related to multiple sclerosis, including inflammatory responses and repair processes.
- nonselective S1P1 agonists have recently It is approved for the treatment of multiple sclerosis.
- S1P receptors are equally widely expressed in many cells involved in the induction of multiple sclerosis.
- S1P1 receptors play a very important role in the immune system.
- the S1P1 receptor is mainly expressed on the surface of lymphocytes such as T cells and B cells, and reacts with S1P to participate in lymphocyte recycling.
- the S1P concentration is higher in body fluid than in lymphoid tissue, so that lymphocytes leave the lymphoid tissue according to the difference in S1P concentration and circulate along the efferent lymph.
- the S1P1 receptor of lymphocytes is down-regulated by the S1P1 agonist, the egress of lymphocytes from the lymphoid tissue does not occur, and eventually autoaggressive causing inflammation and tissue damage to the CNS. The infiltration of lymphocytes is reduced, and the therapeutic effect appears in multiple sclerosis.
- fingolimod a nonselective S1P1 agonist approved as an oral multiple sclerosis treatment, when it is activated by binding to the S1P1 receptor, paradoxically, the receptor is internalized or degraded from the lymphocyte surface, resulting in functional S1P1 It acts as an antagonist.
- Korean Patent Application Laid-Open No. 10-2014-0104376 discloses a novel compound of Formula 1 effective as an S1P receptor agonist.
- X is C or N
- R1 is H or optionally substituted alkyl
- R2 is H, optionally substituted alkyl, halogen, CN, CF 3 or COCF 3 ,
- W is C, N, C-alkoxy, C-halogen or C-CN
- n 0, 1, 2 or 3
- R3 to R10 are each H, alkyl, halogen, halogenoalkyl or alkoxyalkyl,
- R11 is H
- R12 is OH, NH 2 , or to be.
- reaction may have the following problems in producing a clinical API.
- the filtered solid was washed sequentially with water and MTBE, respectively, and then dried over nitrogen to 6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-2H -Naphthalen-1-one was obtained.
- Phosphoryl chloride (POCl 3 ) was added to the reactor and the internal temperature was cooled to 0 °C. DMF was slowly added dropwise, and after stirring at an internal temperature of 50° C. for 2 hours, 6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-2H-naphthalene -1-one was added and reacted at an internal temperature of 50° C. for 3 hours. Since excessive HCl gas was generated during the reaction, a vent line was installed so that it could be neutralized by installing a NaOH trap.
- an object of the present invention is to provide a suitable method for producing the compound of Formula 2, which is a key intermediate in a novel synthesis method of an excellent sphingosine-1-phosphate receptor agonist, in high yield.
- R1 is hydrogen or substituted or unsubstituted alkyl
- R2 is hydrogen, substituted or unsubstituted alkyl, halogen, CN, CF 3 or COCF 3 ;
- X is C or N
- L is a leaving group
- One aspect according to the present invention provides a method for preparing an intermediate compound of Formula 2 below, comprising substituting a leaving group for an alcohol group of the compound of Formula 3 in an ether-based single solvent.
- R1 is hydrogen or substituted or unsubstituted alkyl
- R2 is hydrogen, substituted or unsubstituted alkyl, halogen, CN, CF 3 or COCF 3 ;
- X is C or N
- L is a leaving group
- the 'alkyl' is a substituted alkyl
- substituents there may be one or more substituents, and the substituents are each independently a group consisting of halogen, cyano, hydroxy, alkyloxy, oxo, unsubstituted sulfonyl and sulfonyl substituted with alkyl. It may be selected from
- R1 of the above formula is hydrogen or C 1 -C 6 substituted or unsubstituted alkyl
- R2 is hydrogen, C 1 -C 6 substituted or unsubstituted alkyl, halogen, CN, It may be CF 3 or COCF 3 .
- R1 may be C 1 -C 4 substituted or unsubstituted alkyl, and R2 may be halogenyl (F, Cl, Br or I).
- the leaving group (L) is a reactive group that provides a substitution position to the compound of Formula 2 when the compound of Formula 2 is subjected to a substitution reaction with an alcohol-based compound, but is not limited thereto, for example, chlorine (Cl), bromine (Br), iodine (I), methanesulfonate (Oms), p-toluenesulfonate (OTs) and trifluoromethanesulfonate (OTf) may be selected.
- L may be Br.
- the present invention provides a compound of Formula 2, which is a key intermediate in the synthesis of a sphingosine-1-phosphate receptor agonist by substituting a leaving group for the terminal alcohol group of the compound of Formula 3, specifically, the step of replacing the 'alcohol group with a leaving group' ' (hereinafter, referred to as 'leaving group substitution step') is a technical feature of remarkably lowering the production rate of the N2 isomer by performing it in an ether-based single solvent.
- the 'single solvent' indicates that only one type of solvent is included in the reactor for the leaving group substitution reaction.
- the inclusion of a trace amount of a heterogeneous solvent at a level that does not substantially affect the yield of the reaction product in the reactor for the leaving group substitution reaction is also not excluded from the single solvent.
- the inclusion of a heterogeneous solvent in the content can also be viewed as the use of a single solvent.
- the ether-based solvent is not limited thereto, but for example, dialkyl such as diethyl ether, dipropyl ether, dibutyl ether, diisoamyl ether, ethyl methyl ether, methyl propyl ether, methyl butyl ether, ethyl propyl ether, etc.
- etheric solvents such as diphenyl ether and anisole;
- cyclic ether solvents such as tetrahydrofuran and tetrahydropyran, etc. are mentioned.
- the ether-based single solvent may be methyl tert-butyl ether (MTBE).
- the compound of Formula 3 and MTBE are mixed and cooled to 0° C., and then reacted with PBr 3 to obtain a compound of Formula 2.
- the compound of Formula 3 and MTBE are mixed, cooled to 0° C., reacted with PBr 3 , and then washed with water and filtered to obtain the compound of Formula 2 when the reaction is completed.
- the compound of Formula 3 is prepared according to a method comprising the steps of:
- R1, R2 and X are as defined in Formula 2 or Formula 3,
- R3 is C 1 -C 6 substituted or unsubstituted alkyl.
- R3 may be a C 1 -C 4 substituted or unsubstituted alkyl.
- R3 may be a methyl group.
- step 1) R1 and R2 substituents are introduced into the compound of Formula 4 and crystallized with a crystallization solvent including an alcohol solvent to prepare a compound of Formula 5.
- the alcohol solvent for the crystallization is not limited thereto, but may be, for example, at least one solvent selected from methanol, ethanol, isopropyl alcohol and butanol.
- the solvent for the crystallization may be a mixed solvent of an alcohol solvent and water.
- a mixed solvent of an alcohol solvent and water as the crystallization solvent, there may be an effect of reducing the yield of the N2 isomer.
- the mixed solvent for crystallization has a volume ratio of the alcohol solvent and water in terms of the yield of Chemical Formula 5: 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2, 2:1 to 1:1, or 1.5:1 to 1:1 may be used.
- the solvent for the crystallization may be a mixed solvent of ethanol and water.
- the ethanol and water may be used in an EtOH:H 2 O volume ratio of 2:1 to 1:2, 2:1 to 1:1, 1.5:1 to 1:1, or 1:1.
- the crystallization solvent is a mixed solvent of an alcohol solvent and water
- the alcohol solvent and water may be added sequentially or simultaneously during crystallization, respectively.
- an alcohol solvent such as EtOH
- EtOH is added to the reaction product in which the substituent is introduced, and then cooled to 0 ° C. to 20 ° C., and then water is added to crystallize to obtain a compound of formula 5 it could be
- it may be crystallized after purifying the reaction product in which a substituent is introduced before the crystallization.
- the crystallization yield can be improved by removing unreacted residual compounds used in the reaction.
- the purification may be performed using, for example, a polar solvent, and the polar solvent may be, for example, a polar organic solvent, water, or a mixed solvent thereof.
- the polar organic solvent is not limited thereto, but may be, for example, at least one solvent selected from among ethyl acetate, hexane and dichloromethane.
- the reaction product in which the substituent is introduced may be purified by a mixed solvent of ethyl acetate (EtOAc) and water, and then crystallized to obtain the compound of Formula 5.
- EtOAc ethyl acetate
- the aqueous layer is removed using ethyl acetate and water in a volume ratio of 2:1 to 1:2, It may be crystallized after removing a polar solvent other than water.
- K 2 CO 3 used in the reaction in which the substituent is introduced is together at the time of crystallization of the reaction product It may be to prevent the precipitation or to reduce the precipitation amount to improve the purity of the crystal.
- R1 and R2 may be those in which R1 is substituted and then R2 is substituted, R1 is substituted after R2, or R1 and R2 are simultaneously substituted.
- R2 in the compound of Formula 4, may be substituted before R1.
- R1 when bulky R1 is first substituted in the compound of Formula 4, for example, if bulky R1 is first substituted at the 3rd position of indazole where X is N, the production of the N2 isomer is suppressed, and the yield is improved can be
- step 2) the compound of Formula 5 is reacted with a reducing agent to obtain a compound of Formula 3.
- the reducing agent used in step 2) may use a conventional reducing agent capable of reducing an ester group to an alcohol, for example, sodium borohydride (NaBH 4 ), lithium borohydride (LiBH 4 ), borane (BH) 3 ) and at least one selected from diisobutylaluminum hydride (DIBAH) may be used, but is not limited thereto.
- a conventional reducing agent capable of reducing an ester group to an alcohol for example, sodium borohydride (NaBH 4 ), lithium borohydride (LiBH 4 ), borane (BH) 3 ) and at least one selected from diisobutylaluminum hydride (DIBAH) may be used, but is not limited thereto.
- DIBAH diisobutylaluminum hydride
- the reducing agent may be additionally added according to the progress of the reaction.
- the solvent that was added at the beginning of the reaction may be added together, or only the reducing agent may be added without adding a solvent.
- the reducing agent is used to react the remaining compound of Formula 5 and methanol may have an effect of further improving the yield of the compound of Formula 3 obtained by adding methanol.
- the reaction product may be purified to obtain the compound of Formula 3.
- an organic solvent such as dichloromethane (DCM), isopropyl acetate and ethyl acetate, water, or a mixed solvent thereof may be used for the purification of the reaction product of the reduction reaction.
- DCM and water are added to remove the aqueous layer, thereby further improving the yield of the compound of Formula 3 may be exhibited.
- the compounds prepared according to the present invention can be used as key intermediates for the synthesis of sphingosine-1-phosphate receptor agonists.
- the compound prepared according to the present invention can be used as a main intermediate in a known synthesis method of a sphingosine-1-phosphate receptor agonist, and can also be used as a main intermediate in a new synthesis method developed after the present application.
- the use of the present invention is not limited to a particular method of synthesis of a sphingosine-1-phosphate receptor agonist.
- the compounds prepared according to the present invention can be used for other purposes other than the synthesis of sphingosine-1-phosphate receptor agonists, and the use of the present invention is limited only to the synthesis of sphingosine-1-phosphate receptor agonists. it is not
- the use of the preparation method of the present invention has the effect of mass-producing the compound of Formula 2 in high yield.
- Example 1-1 Synthesis of 3-Chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester (3-Chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester)
- Reaction ion pair chromatography was performed by HPLC, and the reaction was completed (1H-indazole-5-carboxylic acid methyl ester: N/D).
- the external temperature was set to 0° C., and cooling was performed for 60 minutes.
- K 2 CO 3 (10.7 kg, 77.4 mol)
- 2-iodopropane iodopropane, 8.98 kg, 52.8 mol
- B-complex (which is produced by NaBH 4 (3-chloro-1-isopropyl-1H-indazol-5-yl)-methanol alcohol and boron conjugated) and residual NaBH 4
- 3N HCl 39.3 kg was slowly added for 60 minutes to maintain the pH of the reaction solution at 3.0 and distilled under reduced pressure to remove the solvent.
- 5-bromomethyl-3-chloro- 5-bromomethyl-3-chloro- was used in the same manner as in Example 1-3, except that a DCM/MTBE 4:1 mixed solvent was used for the substitution reaction, and DCM instead of water was used for extraction of the reaction product. 1-Isopropyl-1H-indazole was obtained.
- SG15 represents “(3-chloro-1-isopropyl-1H-indazol-5-yl)-methanol
- SG20 represents “ 5-bromomethyl-3-chloro- 1-isopropyl-1H-indazole”.
- 3-chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester was prepared in the same manner as in Example 1-1, except that water was added and crystallized without a purification step. obtained.
- SG10 represents "3-chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester.
- 3-chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester was prepared in the same manner as in Example 1-1 except that EtOH:H 2 O was used in a volume ratio of 3:7 during crystallization. obtained.
- 3-chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester was prepared in the same manner as in Example 1-1 except that EtOH:H 2 O was used in a volume ratio of 1:1 during crystallization. obtained.
- 3-chloro-1-isopropyl-1H-indazole-5-carboxylic acid methyl ester was prepared in the same manner as in Example 1-1 except that EtOH:H 2 O was used in a volume ratio of 7:3 during crystallization. obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un nouveau procédé de préparation d'un composé de formule chimique 2 défini dans la présente description, qui peut être utilisé efficacement pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280028372.8A CN117203189A (zh) | 2021-04-14 | 2022-04-14 | 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0048764 | 2021-04-14 | ||
KR20210048764 | 2021-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022220608A1 true WO2022220608A1 (fr) | 2022-10-20 |
Family
ID=83640840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/005396 WO2022220608A1 (fr) | 2021-04-14 | 2022-04-14 | Procédé de préparation d'un intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102658761B1 (fr) |
CN (1) | CN117203189A (fr) |
WO (1) | WO2022220608A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011518154A (ja) * | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−1−{2−[4’−(3−メトキシプロパン−1−スルホニル)−ビフェニル−4−イル]−エチル}−2−メチル−ピロリジンの合成に有用なプロセス |
KR20140104376A (ko) * | 2013-02-20 | 2014-08-28 | 주식회사 엘지생명과학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
KR20170034902A (ko) * | 2014-07-16 | 2017-03-29 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
KR20200035109A (ko) * | 2017-09-07 | 2020-04-01 | 지앙수 루이케 메디컬 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | 치환된 페닐아세트산 유도체의 제조방법 |
KR20200145735A (ko) * | 2019-06-19 | 2020-12-30 | 주식회사 엘지화학 | 인돌 또는 인다졸 화합물의 제조방법 |
KR20220048950A (ko) * | 2020-10-13 | 2022-04-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1984334B1 (fr) * | 2006-02-15 | 2014-04-09 | Allergan, Inc. | Composes amide d'acide indole-3-carboxylique, ester, thioamide et ester de thiol porteurs de groupes aryl ou heteroaryl presentant une activite biologique antagoniste sur le recepteur sphingosine-1-phosphate (s1p) |
UA107360C2 (en) * | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
TW201206429A (en) * | 2010-07-08 | 2012-02-16 | Merck Serono Sa | Substituted oxadiazole derivatives |
-
2022
- 2022-04-14 WO PCT/KR2022/005396 patent/WO2022220608A1/fr active Application Filing
- 2022-04-14 CN CN202280028372.8A patent/CN117203189A/zh active Pending
- 2022-04-14 KR KR1020220046041A patent/KR102658761B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011518154A (ja) * | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ, インコーポレイテッド | (r)−1−{2−[4’−(3−メトキシプロパン−1−スルホニル)−ビフェニル−4−イル]−エチル}−2−メチル−ピロリジンの合成に有用なプロセス |
KR20140104376A (ko) * | 2013-02-20 | 2014-08-28 | 주식회사 엘지생명과학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
KR20170034902A (ko) * | 2014-07-16 | 2017-03-29 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
KR20200035109A (ko) * | 2017-09-07 | 2020-04-01 | 지앙수 루이케 메디컬 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | 치환된 페닐아세트산 유도체의 제조방법 |
KR20200145735A (ko) * | 2019-06-19 | 2020-12-30 | 주식회사 엘지화학 | 인돌 또는 인다졸 화합물의 제조방법 |
KR20220048950A (ko) * | 2020-10-13 | 2022-04-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
CN117203189A (zh) | 2023-12-08 |
KR102658761B1 (ko) | 2024-04-19 |
KR20220142386A (ko) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020145627A1 (fr) | Procédé de préparation de glufosinate | |
WO2020145514A1 (fr) | Procédé de production de l-glufosinate | |
WO2011071314A2 (fr) | Procédés de préparation de formes cristallines a et b d'ilaprazole et procédé de conversion des formes cristallines | |
WO2010030132A9 (fr) | Procédé de purification d'adefovir dipivoxil | |
WO2011004980A2 (fr) | Procédé de préparation de dérivés tricycliques | |
WO2012030106A2 (fr) | Procédé de production d'un composé intermédiaire pour la synthèse d'un médicament | |
WO2022220612A1 (fr) | Procédé de préparation d'intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate | |
WO2019066467A1 (fr) | Nouveau procédé de préparation d'un composé de (2r)-2-(2-méthoxyphényl)-2-(oxane-4-yloxy)éthane-1-ol, et intermédiaire utilisé à cet effet | |
WO2022220610A1 (fr) | Procédé de préparation d'un intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate | |
WO2011154860A1 (fr) | Procédé amélioré pour la préparation de l'ilopéridone | |
WO2021118003A1 (fr) | Procédé de préparation à haut rendement d'un nouveau bloqueur de fuite vasculaire | |
WO2022220608A1 (fr) | Procédé de préparation d'un intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate | |
WO2022080812A1 (fr) | Procédé de préparation d'intermédiaire pour la synthèse d'un agoniste du récepteur de sphingosine-1-phosphate | |
WO2014010990A1 (fr) | Nouveaux dérivés de pyridine et procédé de préparation d'un composé intermédiaire pour la fabrication d'herbicides de suflonylurée l'utilisant | |
WO2015102234A1 (fr) | Developpement de synthese en enceinte unique de liquide ionique anhydre au moyen d'orthoester de trialkyle | |
WO2012148246A2 (fr) | Procédé de préparation de sitagliptine | |
WO2022220613A1 (fr) | Nouveau procédé de préparation d'un agoniste du récepteur de la sphingosine-1-phosphate | |
WO2022220611A1 (fr) | Nouveau procédé de préparation d'un agoniste du récepteur de la sphingosine-1-phosphate | |
WO2014098410A1 (fr) | Procédé de préparation de monohydrate de bosentan, nouvel intermédiaire utilisé, et son procédé de préparation | |
WO2011105649A1 (fr) | Nouveau procédé de fabrication de la pitavastatine hémicalcium utilisant un nouvel intermédiaire | |
WO2023101115A1 (fr) | Procédé de préparation d'un isomère unique de 1-(1-(2-benzylphénoxy)propan-2-yl)-2-méthylpipéridine de pureté élevée | |
WO2023277658A1 (fr) | Procédé de préparation d'un intermédiaire pour la synthèse d'un inhibiteur de la xanthine oxydase | |
WO2017090991A1 (fr) | Procédé de purification de dérivé de benzopyrane, forme cristalline correspondante et procédé de préparation de la forme cristalline | |
WO2018124644A1 (fr) | Nouveau procédé de préparation d'un composé de thiénopyrimidine et intermédiaire | |
AU2019268945B2 (en) | Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22788463 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280028372.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22788463 Country of ref document: EP Kind code of ref document: A1 |